Medifoxamine

Source: Wikipedia, the free encyclopedia.
Medifoxamine
Clinical data
Trade namesClédial, Gerdaxyl
Other namesMedifoxamine fumarate; N,N-Dimethyl-2,2-diphenoxyethylamine
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability21%[1][2]
Elimination half-life2.8 hours (acute);[1][2]
4.0 hours (chronic)[3]
Identifiers
  • N,N-dimethyl-2,2-diphenoxyethanamine
JSmol)
ChiralityRacemic mixture
  • CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2
  • InChI=1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
  • Key:QNMGHBMGNRQPNL-UHFFFAOYSA-N
  (verify)

Medifoxamine, previously sold under the brand names Clédial and Gerdaxyl, is an

withdrawn from the market in 1999 (Morocco) and 2000 (France) following incidences of hepatotoxicity.[10][12][13]

Pharmacology

Pharmacodynamics

Medifoxamine has been found to act preferentially as a relatively weak

serotonin receptors including 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT3 (>10,000 nM).[3] As medifoxamine is metabolized extensively in the liver during first-pass metabolism, and as these metabolites have as much as 3-fold greater activity relative to medifoxamine, it is likely that they contribute significantly to the pharmacology of the parent drug.[3]

Effectiveness and tolerability

Unlike many

controlled clinical studies have found it to have similar effectiveness to imipramine, clomipramine, and maprotiline in the treatment of depression.[3][9][18][19]

Society and culture

Generic names

Medifoxamine is the

INNTooltip International Nonproprietary Name while médifoxamine is its DCFTooltip Dénomination Commune Française.[6][7][8]

Brand names

Medifoxamine was marketed under the brand names Clédial and Gerdaxyl.[6][7]

References